1	Investor Conference Call 7 December 2007
2	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
3	Introduction 4 Distinct Salesforces in the USA R&D Projects 69 capitalised (26 completed) 113 others (non capitalised) 184 Haemostasis Products 471 Infectious Disease Products 31 Distinct Instrument Types (excl voltage differences)
4	Introduction Key Message from Today
5	Introduction Summary of Write-Off US$m R&D project focus 5.5 Haemostasis product rationalisation 2.9 Infectious disease product rationalisation 0.8 Instrumentation rationalisation 7.8 Swedish factory closure 0.6 Reduction in headcount 1.7 Impairment of Goodwill 20.2 Total 39.5 (Cash Impact US$2m)
6	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
7	Sales Force Reorganisation – Current Structure Multi tasking direct salesforces Germany, UK & France Multiple direct salesforces in USA Haemostasis Infectious Disease Clinical Chemistry (incl A1c) POC Distributors for ROW
8	Sales Force Reorganisation – New Structure Two distinct global divisions Point of Care (POC) Clinical Lab POC Unigold HIV TRI♦stat A1c Unigold LUA Clinical Lab Haemostasis Infectious Disease Clinical Chemistry
9	Sales Force Reorganisation – New Structure POC Executive VP - David Oxley 16 years in public health leadership positions Ex Orasure – head of government relations Delegate to the Board of The Global Fund Clinical Lab Executive VP - Dr. Robert Passas 25 years in clinical diagnostics Ex Abbott – Diabetes Care regional director (Southern Europe, Africa, Middle East & India)
10	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
11	R&D Project Focus Significant R&D effort within Trinity Conducted in Ireland, Germany, New York, California, Kansas at the site of product manufacture Significant number of projects 69 capitalised in accordance with IFRS 26 complete (key projects include Unigold HIV, Unigold LUA, TRI♦stat , EU Lyme Western Blot) 43 ongoing (including Destiny Max, etc) 113 other projects in early stage (non capitalised)
12	R&D Project Focus – Future Focus Future Focus Cut in half the number of projects On-time delivery On-budget delivery 43 Ongoing Projects Keep 20, including Destiny Max, US Lyme, D-Dimer, HIV Incidence Assay Cull 23
13	R&D Project Focus – Future Strategy 23 Culled R&D Projects Once-off non cash write-off of $5.5m Key projects culled include : HIV Western Blot HIV OTC Early stage R&D Projects Reduce by 50%
14	R&D Project Focus – Future Strategy Key Projects FY08 Clinical Lab Haemostasis Destiny Max New D-Dimer (improved performance / robustness) Completed applications necessary for product rationalisation Clinical Chemistry PD2 (successor to PDQ instrument) Infectious Disease Lyme Western Blot automation / enhancement HIV Incidence Assay Point of Care Tristat (HbA1c) – CLIA waiver Unigold HIV enhancements
15	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
16	Haemostasis Product Rationalisation Acquisition History December 2001 : Biopool August 2002 : Sigma / Amax June 2006 : bioMerieux (BMX) Resulted in multiple reagent types and multiple instrument types Initial rationalisation FY06 Further (final) rationalisation Q4 FY07
17	Haemostasis Product Rationalisation Pre cull 184 products Post cull 78 products 6 PT (3 reagent types x 2 vol vials) BMX 6 APTT (3 reagent types x 2 vol vials) BMX 3 Fibrinogen Amax 1 Thrombin BMX 8 Deficient Plasma Biopool 6 Specialty Clotting Assays Amax / Biopool 6 Chromogenic Clotting Amax / Biopool 4 D-Dimer Amax / Biopool 7 Routine Controls BMX / Amax 6 Specialty Controls Amax / Biopool 6 Calibrators BMX / Amax 10 Trinilize Biopool 9 MDA specific BMX
18	Haemostasis Product Rationalisation Selection Criteria Customer choice Robustness in the manufacturing process Cost of production Rationale for Cull Brand awareness (“Trini”) Focused product offering Reduced production costs (currently values assigned for most reagents against most instrument types) Manufacturing efficiencies (larger batches, more frequently) Inventory reduction Less application work (matrix effect)
19	Haemostasis Product Rationalisation 106 Products Culled Once-off non cash write-off of US$2.9m Won’t be culled until applications for alternatives in place Revenues virtually unaffected – substitution effect
20	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
21	Infectious Disease Product Rationalisation 471 products currently offered to customers Proposed Cull 69 finished kits (annualised sales of $700k) 95 components (annualised sales of $100k) Components remain part of finished kits not culled Once-off non cash write-off of $800k
22	Infectious Disease Product Rationalisation Selection Criteria Low value products Less potential for growth Not core to key customers Rationale for Cull More focused product offering Inventory reduction Facilitate reduction in headcount
23	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
24	Instrumentation Rationalisation Multiple instrument types within Trinity – haemostasis & infectious disease Accumulated from various acquisitions Rationale for cull Reduction in training of service engineers and tech support Reduction in applications work (matrix effect – eg haemostasis, 184 reagents and > 20 instruments) Multiple part numbers (8,765 for BMX instruments alone) Need to support instruments for 7 years post cull Inability of service engineers to carry parts in trunk stock Older technology – availability of parts going forward
25	Instrumentation Rationalisation - Haemostasis Core instrument platforms going forward Destiny Max (high throughput) Lemgo produced Launch H2 FY08 On target Destiny Plus (low / medium throughput) Thrombolyzer XRC (OEM’ed in / medium throughput) KC1 / KC4 (manual instrument) Option (OEM’ed in / manual instrument) Final cull of remainder – incremental to FY06 cull
26	Instrumentation Rationalisation - Haemostasis No longer focusing on MDA (high throughput) (ex BMX) Will be replaced by Max (double throughput) Will continue to support MDA to end of its life cycle Currently pre-selling Max Customers deferring purchasing decision until launch of Max MTX (low / medium throughput) (ex BMX) Back-up instrument to MDA Destiny Plus will be back-up to Destiny Max XM (manual instrument) (ex BMX) To be replaced by KC1 / KC 4 / Option
27	Instrumentation Rationalisation - Haemostasis No longer focusing on Thrombolyzer Max / Compact XR / Compact X / Compact / Chrom / Combi OEM’ed in instruments Ex BMX acquisition No longer produced by OEM supplier Amax 190 / Amax 200 (low / medium throughput) Pre-cursor to Destiny Plus Lemgo produced Amax 400 (high throughput) To be replaced by Destiny Max Was Lemgo produced Others KC 40, Miniquant
28	Instrumentation Rationalisation – Infectious Disease Core instrument platforms going forward Nexgen Adaltis produced 3^rd party supplier DSX Dynex produced 3^rd party supplier
29	Instrumentation Rationalisation – Infectious Disease No longer focusing on XL’s Old technology Remainder being sold to China Plab / Labotech Ex Adaltis No longer produced Nexgen is latest Adaltis instrument Others Denleys, ELX, Well Preps, Autoblots, MicroLab AT Plus Once-off non cash incremental write-off of $7.8m
30	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
31	Swedish Factory Closure Existing factories within Trinity Bray, Ireland Jamestown, New York Carlsbad, CA Kansas City, MO Lemgo, Germany Umea, Sweden Sweden acquired as part of Biopool acquisition, December 2001 Currently manufacture EIA’s and components for Bray haemostasis products
32	Swedish Factory Closure Proposed Move EIA’s to Jamestown, NY (EIA centre of excellence) Remainder to Bray, Ireland (haemostasis centre of excellence) Timing Training by end March 2008 Equipment transfer : February – June 2008 Final validation / initial production builds : Jamestown : October 2008 Bray : December 2008
33	Swedish Factory Closure Severance payments US$287k Inventory / fixed assets write off US$194k Termination of lease US$97k Annualised savings US$500k (full year effect in FY09)
34	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
35	Reduction in Headcount Rationalisation of products, instruments and R&D projects = reduction in headcount $5m reduction in budgeted FY08 wages Counteracting the impact of FX and inflation in FY08 Currency impact is affecting wages bill Average US$ / € rate YTD = 1.37 Current US$ / € rate = 1.47
36	Average $/€ FX Rate
37	Reduction in Headcount Impact of reduction in headcount = redundancy payments of US$1.7m Rationalisation of workforce complete pre year end Across all operations
38	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
39	Impairment of Goodwill Accounting standards (IAS 36) require assessment of goodwill / intangibles when share price / market cap is low Result is an impairment of our goodwill by US$20.2 million Non-cash accounting adjustment driven by current share price
40	Agenda Introduction Sales Force Reorganisation R&D Project Focus Haemostasis Product Rationalisation Infectious Disease Product Rationalisation Instrumentation Rationalisation Swedish Factory Closure Reduction in Headcount Impairment of Goodwill 2008 Goals
41	2008 Goals Restructure US salesforce (Q1) Launch Haemostasis Trini brand (Q1) Appoint Tristat distribution partners (Q1) Tristat CLIA waiver (Q1) Launch HIV Incidence Assay (Q2) Launch Destiny Max H2 FY08 (H2)